Clearside Biomedical, Inc. (CLSD)

Clearside Biomedical Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	8.23	1.33	29.58	7.89	2.17
Revenue Growth (YoY)	519.89%	-95.51%	274.65%	263.28%	7143.33%
Cost of Revenue	0.36	0.2	0	0	0
Gross Profit	7.87	1.12	29.58	7.89	2.17
Selling, General & Admin	11.87	11.77	11.67	10.76	16.82
Research & Development	20.85	19.63	18.54	15.07	15.66
Other Operating Expenses	0	0	0	0.28	0.47
Operating Expenses	32.72	31.4	30.2	26.1	32.94
Operating Income	-24.84	-30.28	-0.63	-18.21	-30.77
Other Expense / Income	7.64	2.67	-1	-	-
Pretax Income	-32.49	-32.95	0.38	-18.21	-30.77
Net Income	-32.49	-32.95	0.38	-18.21	-30.77
Shares Outstanding (Basic)	62	60	58	47	38
Shares Outstanding (Diluted)	62	60	60	47	38
Shares Change	2.66%	0.50%	28.81%	21.84%	24.20%
EPS (Basic)	-0.53	-0.55	0.01	-0.39	-0.81
EPS (Diluted)	-0.53	-0.55	0.01	-0.39	-0.81
Free Cash Flow	-19.91	-13.61	-10.73	-13.18	-27.09
Free Cash Flow Per Share	-0.32	-0.23	-0.18	-0.28	-0.71
Gross Margin	95.68%	84.63%	100.00%	100.00%	100.00%
Operating Margin	-302.02%	-2281.61%	-2.12%	-230.68%	-1416.01%
Profit Margin	-394.91%	-2482.82%	1.27%	-230.68%	-1416.01%
Free Cash Flow Margin	-242.06%	-1025.70%	-36.29%	-166.90%	-1246.80%
EBITDA	-32.42	-32.8	0.55	-18.03	-30.56
EBITDA Margin	-394.09%	-2471.89%	1.87%	-228.40%	-1406.30%
Depreciation & Amortization	0.07	0.15	0.18	0.18	0.21
EBIT	-32.49	-32.95	0.38	-18.21	-30.77
EBIT Margin	-394.91%	-2482.82%	1.27%	-230.68%	-1416.01%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).